Suzhou Basecare Medical Corp. Ltd. Class H (2170) AI Stock Analysis

• Market Cap: HK$588.08M
• Dividend Yield: N/A
• Average Volume (3M): 121.73K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.30
• Revenue Growth: 11.43%
• EPS Growth: 4.88%
• Country: HK
• Employees: 497
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.44
• Shares Outstanding: 82,713,840
• 10 Day Avg. Volume: 98,950
• 30 Day Avg. Volume: 121,733
• PEG Ratio: -0.12
• Price to Book (P/B): 0.62
• Price to Sales (P/S): 2.35
• P/FCF Ratio: -2.18
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -4.2
• Revenue Forecast (FY): HK$2.79B

• Rating: 44 Neutral
• Price Target: HK$2.00 ▼(-6.54% Downside)

The overall stock score of 44 reflects significant challenges in financial performance, technical analysis, and valuation. The company's strong revenue growth is overshadowed by high operating costs and leverage risks, while bearish technical indicators and a negative P/E ratio further weigh down the score. Improvement in operational efficiency and financial stability is crucial for enhancing the stock's attractiveness.

Positive Factors

Revenue Growth

The company's strong revenue growth indicates successful market penetration and product adoption, which can drive long-term business expansion and stability.

Product Diversification

A diversified product portfolio reduces dependency on a single revenue stream, enhancing resilience against market fluctuations and supporting sustainable growth.

Innovation Focus

Continuous innovation through R&D strengthens competitive advantage and positions the company to adapt to industry changes, ensuring long-term relevance.

Negative Factors

High Operating Costs

High operating costs can erode profit margins and limit the company's ability to reinvest in growth initiatives, potentially impacting long-term profitability.

Leverage Risks

Excessive leverage can strain financial resources, increasing vulnerability to economic downturns and limiting strategic flexibility.

Cash Flow Challenges

Negative cash flow from operations indicates difficulty in generating cash internally, which may necessitate external financing and affect financial health.

Suzhou Basecare Medical Corp. Ltd. Class H Business Overview & Revenue Model

Company Description

Suzhou Basecare Medical Corp. Ltd. Class H (2170) is a prominent healthcare company based in China that specializes in the development, manufacturing, and commercialization of advanced medical devices and diagnostic solutions. The company operates primarily in the fields of medical imaging, in vitro diagnostics, and healthcare information technology. With a strong focus on innovation, Basecare aims to enhance patient care through its cutting-edge products and services designed to improve clinical outcomes across various medical disciplines.

How the Company Makes Money

Suzhou Basecare Medical Corp. Ltd. generates revenue through multiple streams, primarily by selling its medical devices and diagnostic products to hospitals, clinics, and healthcare providers. The company benefits from a diversified product portfolio, including imaging systems and diagnostic kits, which contribute significantly to its sales. Additionally, Basecare may engage in strategic partnerships with other medical technology firms or research institutions to co-develop products, thereby expanding its market reach and enhancing its revenue potential. The company's focus on research and development enables it to innovate continuously, which helps maintain a competitive edge and drives sales growth. Furthermore, Basecare may also generate income through service contracts, maintenance agreements, and training programs related to its products.

Suzhou Basecare Medical Corp. Ltd. Class H Financial Statement Overview

Summary

Suzhou Basecare Medical Corp. Ltd. exhibits robust revenue growth driven by increased sales, but struggles with profitability due to high operating costs. The balance sheet indicates a sound equity base but is offset by high leverage, posing risks in financial stability. Cash flow generation remains a critical challenge, with persistent operational cash deficits undermining financial resilience.

Income Statement

The company shows strong revenue growth with a consistent increase in total revenue over the years, indicating solid sales expansion. However, the net profit margin remains negative due to high operating expenses, impacting overall profitability. The gross profit margin is healthy, suggesting effective cost management in production, but the negative EBIT and EBITDA margins highlight ongoing challenges in operating efficiency.

Balance Sheet

The balance sheet reflects a stable equity base with a solid equity ratio, indicating strong capital structure. However, the high debt-to-equity ratio suggests potential leverage risk. The positive cash and short-term investments position bolsters liquidity, yet the negative net income limits return on equity, which remains a concern for investors.

Cash Flow

The cash flow statement shows consistent negative operating cash flow, raising concerns about the company's ability to generate cash from its core operations. The free cash flow position is improving, yet still negative, highlighting challenges in sustaining growth without external financing. The inability to convert operating cash flow to net income efficiently is a key area that needs attention.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	275.71M	299.11M	207.98M	140.90M	107.30M	81.11M
Gross Profit	131.54M	136.22M	91.35M	59.53M	51.15M	27.71M
EBITDA	-226.62M	-253.30M	-174.14M	-117.73M	-118.88M	-873.32M
Net Income	-238.59M	-237.03M	-191.69M	-123.16M	-143.65M	-877.05M
Balance Sheet
Total Assets	1.57B	1.67B	1.90B	1.78B	1.80B	350.30M
Cash, Cash Equivalents and Short-Term Investments	545.48M	684.63M	945.71M	1.33B	1.52B	192.32M
Total Debt	342.23M	328.42M	281.92M	75.54M	48.57M	31.47M
Total Liabilities	535.35M	527.47M	499.98M	188.33M	85.85M	68.96M
Stockholders Equity	1.03B	1.14B	1.40B	1.59B	1.72B	281.33M
Cash Flow
Free Cash Flow	-297.35M	-322.41M	-371.44M	-317.52M	-234.71M	-72.38M
Operating Cash Flow	-207.59M	-229.12M	-267.23M	-188.77M	-197.85M	-64.29M
Investing Cash Flow	-1.63M	-181.19M	-324.81M	-88.70M	-56.60M	33.53M
Financing Cash Flow	-2.45M	33.78M	190.55M	23.51M	1.60B	207.47M

Suzhou Basecare Medical Corp. Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.14
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2170, the sentiment is Negative. The current price of 2.14 is below the 20-day moving average (MA) of 2.33, below the 50-day MA of 2.71, and below the 200-day MA of 3.03, indicating a bearish trend. The MACD of -0.17 indicates Positive momentum. The RSI at 27.68 is Positive, neither overbought nor oversold. The STOCH value of 25.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2170.

Suzhou Basecare Medical Corp. Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2170	44 Neutral	HK$588.08M	―	-20.60%	―	11.43%	4.88%
2235	44 Neutral	HK$2.81B	―	-1.39%	―	49.86%	80.35%
2160	43 Neutral	HK$2.70B	509.09	0.22%	―	-4.38%	―
2500	41 Neutral	HK$1.13B	-1.62	-26.80%	―	-8.56%	-14.84%
2216	40 Neutral	HK$1.31B	-10.19	-8.93%	―	-30.60%	28.61%
9996	39 Underperform	€3.87B	-15.77	-11.20%	―	29.25%	9.02%

Suzhou Basecare Medical Corp. Ltd. Class H Corporate Events

Suzhou Basecare Medical Reports Interim Results Amidst Continued Innovation

Suzhou Basecare Medical Corp. Ltd. reported its interim financial results for the first half of 2025, showing a revenue decline to RMB 101,338,000 from RMB 124,739,000 in the same period of 2024. Despite the revenue drop, the company continues to innovate, having launched several advanced products in genetic testing, andrology diagnosis, and embryo culture, which are expected to enhance clinical outcomes and expand their market presence.

The most recent analyst rating on (HK:2170) stock is a Hold with a HK$3.50 price target. To see the full list of analyst forecasts on Suzhou Basecare Medical Corp. Ltd. Class H stock, see the HK:2170 Stock Forecast page.

Suzhou Basecare Secures NMPA Approval for VitBase Embryo Processing Fluid

Suzhou Basecare Medical Corporation Limited has received approval from the National Medical Products Administration of China for its GEMS series embryo culture medium, specifically the VitBase embryo processing fluid. This approval marks a significant milestone for the company, as it becomes one of the few globally to hold CE, FDA, and TGA certifications for assisted reproductive fluids. The product is based on over 30 years of clinical experience and aims to enhance accessibility and supply chain security in China, positioning the company strongly in the IVF market.

The most recent analyst rating on (HK:2170) stock is a Hold with a HK$3.50 price target. To see the full list of analyst forecasts on Suzhou Basecare Medical Corp. Ltd. Class H stock, see the HK:2170 Stock Forecast page.

Suzhou Basecare Medical Announces Board Meeting for Interim Results

Suzhou Basecare Medical Corp. Ltd. has announced a board meeting scheduled for August 29, 2025, to discuss and approve the interim results for the first half of the year and consider the recommendation of an interim dividend. This meeting is crucial as it will provide insights into the company’s financial performance and potential shareholder returns, impacting its market positioning and stakeholder interests.